Brief: Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models
03/03/2026 13:48
March 3 (Reuters) - Propanc Biopharma Inc PPCB.O: PROPANC BIOPHARMA’S LEAD ASSET PRP SHOWS >85% TUMOR GROWTH INHIBITION IN PRECLINICAL PANCREATIC MODELS Source text: ID:nGNXlyVpc Further company coverage: PPCB.O ((Reuters.Briefs@thomsonreuters.com;))